ZURICH, Oct 18 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8,016 points on Tuesday, according to premarket indications by bank Julius Baer .
The following are some of the main factors expected to affect Swiss stocks:
* Alcon, Novartis’ eye care division, announced the U.S. launch of the CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology (AAO), Oct. 15-18 in Chicago, where it will host a live training programme and present additional data during poster and oral sessions.
* Actelion said a series of recently published scientific articles describing the unique profile of the company’s orally-active antimalarial compound, ACT-451840, has reinvigorated interest in the compound. Actelion is in discussions to find a partner with the expertise and resources to bring this promising therapy to patients.
* Kuehne und Nagel said gross profit for the first nine months of 2016 rose 6.3 percent year on year to 4.9 billion Swiss francs. Its EBITDA improved 5.1 percent to 817 million francs, the company said.
* Clariant announced the official opening of its new polypropylene catalyst production facility in Louisville, KY, USA.
* Sika said it has agreed to acquire Ronacrete (Far East) Ltd., a supplier of repair mortars, tile adhesives and other mortar products in Hong Kong. The company said the acquisition is in line with its global expansion of the mortar business, a component of its “Strategy 2018”. The Ronacrete plant brings Sika’s mortar footprint to 89 factories worldwide, Sika said.
* Swiss competition authority WEKO said it will more closely examine the takeover of Pharmapool Aktiengesellschaft by Galenica subsidiary, Galexis AG. WEKO said there were indications that the combination could create or strengthen a market-dominant position.
* Cassiopea SpA announced the results of its proof of concept trial of its novel topical antibiotic CB-06-01 in subjects with moderately to severe acne and the decision to proceed with further development. The results suggested CB-0601 could potentially be an efficacious drug for the selected indication, though further investigations will be needed to assess the full drug potential, the company said.
* The European Technology and Travel Services Association (ETTSA) said lastminute.com will join the association as a new member.
* Bank Linth LLB said it is now offering clients Apple Pay.
* ADC Therapeutics said it had raised $105 million through a private placement.
* Altin AG said Alpine Select AG and Absolute Invest AG have called for an extraordinary general meeting to take place as soon as feasible and that the following item be brought forward: Accumulation of a dividend: the payout of a dividend of 18 Swiss francs per share.
* Romande Energie Holding said Pierre Oberson, the head of its general secretariat, will leave the company on Jan 31.
Reporting by Zurich newsroom